Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

GD2-directed immunotherapies improve survival of high-risk neuroblastoma (NB) patients (pts). Treatment with chimeric anti-GD2 antibodies (Ab), such as ch14.18, can induce development of human anti-chimeric Ab (HACA). Here, we report HACA effects on ch14.18/CHO pharmacokinetics, pharmacodynamics and...

Full description

Bibliographic Details
Main Authors: Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Juliet Gray, Alberto Garaventa, Carla Manzitti, Shifra Ash, Thomas Klingebiel, James Beck, Victoria Castel, Dominique Valteau-Couanet, Hans Loibner, Ruth Ladenstein, Holger N. Lode
Format: Article
Language:English
Published: MDPI AG 2018-10-01
Series:Cancers
Subjects:
neuroblastoma
anti-GD2 immunotherapy
ch14.18/CHO
pain
long-term infusion
HACA
complement dependent cytotoxicity
Online Access:http://www.mdpi.com/2072-6694/10/10/387

Internet

http://www.mdpi.com/2072-6694/10/10/387

Similar Items